Who are VivoSim Labs, Inc.'s main suppliers?

VivoSim Labs, Inc. (VIVS) key suppliers include: VISCIENT, Eli Lilly and Company, Matinas BioPharma Holdings, Inc.. View the full supplier network at chainsifter.com/chain/VIVS.

Who are VivoSim Labs, Inc.'s major customers?

VivoSim Labs, Inc. (VIVS) key customers include: VISCIENT, Eli Lilly and Company, Eli Lilly and Company, BICO-GROUP, VISCIENT-BIOSCIENCES-INC. View the full customer network at chainsifter.com/chain/VIVS.

What sector is VivoSim Labs, Inc. in?

VivoSim Labs, Inc. (VIVS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

VivoSim Labs, Inc. Suppliers, Customers & Supply Chain (VIVS)

3Suppliers

5Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

VivoSim Labs, Inc. (VIVS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

11Total relationships

3Distinct source URLs

5High confidence

0.787Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

VivoSim Labs, Inc. Suppliers

Ticker	Name	Confidence	Evidence
VISCIENT	VISCIENT	92%	For the three and nine months ended December 31, 2025, the Company incurred $ 213,000 and $ 428,000 in R&D consulting expenses from Viscient, respectively.
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from LLY grap…
MTNB	Matinas BioPharma Holdings, Inc.	72%	Reciprocal relationship from MTNB graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from MTNB graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from MTNB g…

VivoSim Labs, Inc. Customers

Ticker	Name	Confidence	Evidence
VISCIENT	VISCIENT	92%	Additionally, for the three and nine months ended December 31, 2025 and 2024, the Company provided approximately $ 5,000 and $ 4,000 of histology services to Viscient, respectively.
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VIVS graph: Reciprocal relationship from LLY grap…
LLY	Eli Lilly and Company	72%	Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 37 PART III 38 Item 10. Directors, Executive Officers and Corporate Governance 38 Item 11. Executive Compensation 38 Item …
BICO-GROUP	BICO-GROUP	62%	is time to us, as disclosed in our filings, and we may therefore compete with Viscient for the time commitments of our Executive Chairman from time to time. We may be subject to security breaches or …
VISCIENT-BIOSCIENCES-INC	VISCIENT-BIOSCIENCES-INC	62%	is time to us, as disclosed in our filings, and we may therefore compete with Viscient for the time commitments of our Executive Chairman from time to time. We may be subject to security breaches or …

VivoSim Labs, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VIVS-DEBT	Debt stack $812,000	90%	Market cache reports total debt of $812,000.
VIVS-DEBT-13372	Warrants outstanding: 8647	90%	xbrl warrant detail from xbrl 2019-09-30.
VIVS-DEBT-13373	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2014-03-31.

VivoSim Labs, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for VivoSim Labs, Inc..

VivoSim Labs, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for VivoSim Labs, Inc..

VivoSim Labs, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ACIU	AC Immune SA	100.00	2
INCY	Incyte Corporation	100.00	2
ALEC	Alector, Inc.	100.00	2
BYSI	BeyondSpring Inc.	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
IMNM	Immunome, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
ACRS	Aclaris Therapeutics, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
NVO	Novo Nordisk A/S	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
IVA	Inventiva S.A.	100.00	2

VivoSim Labs, Inc. Supply Chain